Vericel Corp (NASDAQ:VCEL)
| 33.83 Delayed Data As of Dec 08 |  -0.41 / -1.20%Today’s Change | 22.16 Today|||52-Week Range 39.90 | +28.44% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.6B |
Company Description
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Contact Information
Vericel Corp. 64 Sidney Street Cambridge Massachusetts 02139-4170 |
Employees
Shareholders
| Mutual fund holders | 60.20% |
| Individual stakeholders | 5.95% |
| Other institutional | 48.24% |
Top Executives
| Dominick C. Colangelo | President, Chief Executive Officer & Director |
| Michael Halpin | Chief Operating Officer |
| Joseph A. Mara | Chief Financial Officer & Treasurer |
| Jonathan Mark Hopper | Chief Medical Officer |
| Sean C. Flynn | Secretary, Senior Vice President & General Counsel |
